Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Alan Celik
Rigshospitalet
,
Afdeling for Kræftbehandling
2022
2024
Publikationer pr. år
Vis
Fingeraftryk
Netværk
Publikationer
(5)
Lignende profiler
(12)
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Alan Celik er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Keyphrases
Advanced Breast Cancer
33%
Advanced Triple-negative Breast Cancer
33%
Alternative Chemotherapy
8%
Basal-like
13%
Biosimilar
33%
Brain Development
33%
Brain Metastases
33%
Breast Cancer
100%
Breast Cancer Diagnosis
33%
Breast Cancer Genomics
33%
Capecitabine
30%
Capecitabine Monotherapy
33%
Chemotherapy
13%
Confidence Interval
33%
Copenhagen
33%
Denmark
16%
Dual Blockade
33%
ER-negative
16%
Estrogen Receptor-negative
8%
Estrogen Receptor-positive
8%
Female Patients
8%
Genomic Studies
33%
HER2-positive Metastatic Breast Cancer
33%
High Risk
25%
High Tumor Burden
16%
Human Epidermal Growth Factor Receptor
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
67%
Inclusion Criteria
8%
Locally Recurrent
11%
Luminal Breast Cancer
13%
Median Overall Survival
36%
Median Progression-free Survival
44%
Metastatic Breast Cancer
41%
Metastatic Triple-negative Breast Cancer
33%
Molecular Subtypes
33%
Normal Breast
33%
Oncology Department
13%
Overall Survival
78%
Pertuzumab
30%
Population-based
33%
Primary Diagnosis
16%
Progression-free Survival
41%
Real-word Study
8%
Survival Median
22%
Targeted Therapy
8%
Third-line Treatment
33%
Trastuzumab
41%
Treatment Line
27%
Treatment Regimen
33%
Triple-negative Breast Cancer
22%
Pharmacology, Toxicology and Pharmaceutical Science
Biosimilar Agent
33%
Brain Metastasis
26%
Breast Cancer
73%
Cancer Growth
6%
Capecitabine
33%
Chemotherapy
11%
Disease
12%
Epidermal Growth Factor Receptor
5%
Epidermal Growth Factor Receptor 2
33%
Estrogen Receptor
11%
First-Line Chemotherapy
6%
Gamma Urogastrone
39%
Metastatic Breast Cancer
67%
Monotherapy
33%
Neoplasm
13%
Overall Survival
65%
Pertuzumab
29%
Population Study
5%
Progression Free Survival
63%
Recurrent Disease
5%
Retrospective Study
39%
Trastuzumab
40%
Vinorelbine
6%
Medicine and Dentistry
Breast Cancer
75%
Cancer Diagnosis
33%
Capecitabine
36%
Disease
9%
Epidermal Growth Factor Receptor
5%
Estrogen Receptor
11%
Gamma Urogastrone
5%
Monotherapy
33%
Oncology
11%
Overall Survival
33%
Progression Free Survival
30%
Retrospective Study
33%
Targeted Therapy
5%
Triple Negative Breast Cancer
33%
